Praxis Precision Medicines Inc (PRAX)
45.27
+0.06
(+0.13%)
USD |
NASDAQ |
May 17, 16:00
45.27
0.00 (0.00%)
After-Hours: 20:00
Praxis Precision Medicines Cash from Financing (Quarterly): 182.76M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 182.76M |
| December 31, 2023 | 4.126M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 69.68M |
| March 31, 2023 | 18.07M |
| December 31, 2022 | 5.387M |
| September 30, 2022 | 3.365M |
| June 30, 2022 | 0.504M |
| March 31, 2022 | 1.209M |
| Date | Value |
|---|---|
| December 31, 2021 | 7.713M |
| September 30, 2021 | 0.212M |
| June 30, 2021 | 99.38M |
| March 31, 2021 | 0.276M |
| December 31, 2020 | 202.06M |
| September 30, 2020 | 108.91M |
| June 30, 2020 | 23.45M |
| March 31, 2020 | -30.00M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-30.00M
Minimum
Mar 2020
202.06M
Maximum
Dec 2020
41.01M
Average
5.387M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 141.05M |
| Regeneron Pharmaceuticals Inc | 47.10M |
| Atossa Therapeutics Inc | 0.204M |
| ADMA Biologics Inc | -1.447M |
| Viking Therapeutics Inc | 606.04M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.86M |
| Cash from Investing (Quarterly) | -91.22M |
| Free Cash Flow | -99.15M |
| Free Cash Flow Per Share (Quarterly) | -1.50 |
| Free Cash Flow to Equity (Quarterly) | -20.86M |
| Free Cash Flow Yield | -23.82% |